You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to use the funds to improve patient engagement and navigation within its Genome Care Delivery technology platform.
The company will use the funds to support its growth in the custom probiotics market, scale delivery of its products, and publish new studies.
The New York-based firm will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various sold cancer types.
ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.
The Oxford, UK-based firm announced the closure of a seed financing round this week as well as plans to develop a methylation-based blood test for early-stage cancer detection.
The startup aims to develop a low-cost, high-throughput proteomics platform that combines biochemistry with computer science and information technology.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The company will use proceeds from the offering to pay off debt related to other notes and to partially fund a redemption of other notes.
The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.
The company said the funds will support the continued development and commercialization of its genome-wide methylation assay for multi-cancer early detection.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.